Stoke Therapeutics Charts Future at Needham Conference with RNA Breakthrough

BEDFORD, MA – April 08, 2026 – Stoke Therapeutics (Nasdaq: STOK) is set to take the virtual stage at the 25th Annual Needham Virtual Healthcare Conference next week, a key moment for the biotechnology firm as it advances its lead drug candidate for a severe form of pediatric epilepsy. CEO Ian F. Smith’s presentation on April 14 is highly anticipated by investors, who will be looking for updates on the company’s pivotal Phase 3 study, its robust financial position, and the strategic path forward for its innovative RNA-based medicine, zorevunersen.

Buoyed by a year of remarkable stock performance and a strategic partnership with industry giant Biogen, Stoke is positioning itself as a leader in developing therapies for genetic diseases caused by protein deficiencies. The company's progress with zorevunersen for Dravet syndrome represents a potential paradigm shift, moving beyond symptom management to target the underlying cause of the disease.

A New Approach to a Devastating Disease

Dravet syndrome is a rare, catastrophic, and lifelong form of epilepsy that begins in the first year of life. While existing treatments primarily focus on controlling the relentless seizures that characterize the condition, they often fall short of addressing the profound developmental delays, cognitive impairment, and behavioral issues that accompany it. This leaves a significant unmet need for therapies that can alter the course of the disease itself.

Stoke Therapeutics aims to fill this void with its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. Unlike gene therapies or traditional drugs, TANGO utilizes antisense oligonucleotides (ASOs) to precisely interact with RNA and restore protein expression from healthy genes. In many Dravet syndrome patients, the condition is caused by a mutation in one of two copies of the SCN1A gene, leading to a roughly 50% reduction in a critical protein called NaV1.1. This deficiency, known as haploinsufficiency, disrupts normal brain function.

Zorevunersen is designed to bind to the RNA transcribed from the healthy, non-mutated copy of the SCN1A gene. This action increases the production of functional NaV1.1 protein, aiming to restore levels closer to normal. The goal is not just to reduce seizure frequency but to achieve true disease modification, potentially improving cognition, motor skills, and overall quality of life for patients. The promise of this approach was recently highlighted by the publication of early clinical data in the New England Journal of Medicine in March 2026, lending significant scientific validation to the program.

Navigating the Path to Market

The journey of zorevunersen through clinical development has been marked by several key milestones that underscore its potential. The drug is currently being evaluated in a global, pivotal Phase 3 study, with a data readout anticipated in mid-2026. A positive outcome from this trial would pave the way for regulatory submissions for market approval.

The U.S. Food and Drug Administration (FDA) has already granted zorevunersen multiple significant designations that could expedite its path to patients. In December 2024, it received Breakthrough Therapy Designation, a status reserved for drugs that demonstrate substantial improvement over available therapies for serious conditions. This is complemented by Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA), as well as Rare Pediatric Disease Designation from the FDA.

These regulatory accolades are not merely symbolic; they provide tangible benefits, including enhanced guidance from regulators, potential for accelerated review timelines, and extended market exclusivity upon approval. For a company like Stoke, they also serve as a powerful validation of the drug's innovative mechanism and its potential to address a critical unmet medical need.

Financial Strength and Strategic Alliances

Stoke’s scientific progress is backstopped by a formidable financial and strategic foundation. The company reported a dramatic 404% increase in revenue for 2025, reaching $184.42 million, primarily driven by its collaboration with Biogen. This influx of capital helped slash the company’s net loss by over 92% and has extended its cash runway into 2028, providing ample funding to see zorevunersen through its late-stage development and potential launch.

This financial health is reflected in its stock performance, which has seen a staggering 455% gain over the past year. While recent insider selling has drawn some notice, the consensus among market analysts remains overwhelmingly positive, with an average 12-month price target suggesting further upside from its current trading price of around $32 per share.

The cornerstone of Stoke's commercial strategy is its 2022 collaboration with Biogen. Under the agreement, Stoke retains exclusive commercialization rights for zorevunersen in the key North American markets of the United States, Canada, and Mexico. Biogen, in turn, gains exclusive rights to commercialize the drug in the rest of the world. This partnership is a strategic masterstroke, allowing Stoke to leverage Biogen’s global infrastructure and commercial expertise while retaining control and maximizing value in its home territory. It significantly de-risks the enormous expense of a global product launch and validates the potential of the TANGO platform.

As CEO Ian F. Smith prepares for the Needham conference, investors will be eager for updates on the Phase 3 trial's progress and the company's pre-commercialization activities. The presentation will also be an opportunity for the company to showcase the broader potential of its TANGO platform, which includes a second candidate, STK-002, in Phase 1 trials for autosomal dominant optic atrophy (ADOA), another disease caused by haploinsufficiency. The upcoming presentation will be a critical forum for Stoke to articulate its vision for the future, both for its lead program and its underlying technology.